News

Our newsletter for Q1 2021 features a commentary on the perceived increase in requests to access N-glucuronides, as well as highlighting Hypha’s solutions for synthesising and characterizing these and other types of glucuronide metabolites, as part of the tools in our One-Stop Metabolite Shop approach.

Project Manager and Head of Chemistry Richard Phipps, together with Hypha scientists Renia Gemmell, Chloe Herring and Chris Drake have received great feedback for the successful completion of a challenging metabolite project for a US pharma client. The project involved multiple disciplines of microbial biotransformation, purification and structure elucidation.

Hypha’s paper in ACS Medicinal Chemistry Letters on “Biotransformation: Impact and Application of Metabolism in Drug Discovery” was published in August 2020.

Check out a new white paper describing the joint efforts of Hypha and Galchimia, who together successfully synthesised metabolites of the herbicide napropamide using a complementary approach of chemical synthesis and microbial biotransformation. The joint project was successful in providing a comprehensive family of compounds relevant for the risk assessment of napropamide.

Hypha were honoured to be asked to contribute a chapter on “Metabolite Generation and Metabolite Characterization by NMR” in the book just published on “Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters”, edited by Shuguang Ma and Swapan Chowdhury.

Hypha are excited to announce they have relocated from Slough to Milton Park in Oxfordshire, one of the largest science clusters in the UK.

Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites.

Great to see Hypha recognised for producing a glucuronide metabolite of praliciguat (M3) in the paper just out in the journal Pharmacology Research & Perspectives.

Hypha remain fully operational and are monitoring the COVID-19 situation closely. We have implemented a number of measures in response to the guidelines issued by the UK Government to ensure that our clients’ projects proceed as planned, while preserving the health and safety of our staff and the wider community.